This Company Just Extended its Reach into the United Kingdom by Opening its First Ketamine Therapy Clinic

Photo by cottonbro from Pexels

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Pasithea Therapeutics Corp. KTTA announced that its wholly owned subsidiary Pasithea Clinics has partnered with ZEN Healthcare to offer intravenous (IV) ketamine therapy to patients suffering from treatment-resistant mental health issues. The treatment will be offered in London’s Knightsbridge district beginning this month. 

“With mental health cases on the rise, fueled even more so by the pandemic, new treatment therapies are urgently needed for those patients who are not responding to traditional treatments,” said Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics. “Evidence from dozens of trials over the past 2 decades consistently supports the efficacy of ketamine in improving symptoms in some mental health disorders. We are thrilled to be able to provide this new treatment approach in the U.K. for those patients who are deemed eligible to receive it.” 

According to FutureWise Research, the global resistant depression treatment market is expected to be valued at over $1 billion by the end of 2026, with an expected compound annual growth rate of 3% from 2019 to 2026.

Ketamine is a U.S. Food and Drug Administration (FDA)-approved drug introduced to the medical community as an anesthetic more than 50 years ago. It has recently been repurposed for the treatment of psychiatric disorders using significantly lower doses than in anesthesia and is now gaining ground as a promising treatment for mental health disorders. In certain psychiatric conditions, such as treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), it has shown remarkable efficacy and a rapid and sustained effect.

Helping Heal the Mind

Major depression is the leading cause of long-term disability worldwide, according to the World Health Organization. Existing treatments have limited success rates, numerous side effects and onset of action delayed by several weeks. Studies have shown that up to 70% of those who receive IV ketamine treatment can eventually show a clinical response. While the number of treatments suggested is done on a case-by-case basis, a typical treatment plan consists of up to 6 infusions in intervals of 2 to 3 weeks.

Pasithea Therapeutics Corp. is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Some of the reputable global companies in the $1.2 trillion industry include COMPASS Pathways plc CMPS, Field Trip Health Ltd. FTRP FTRP and Cybin Inc. CYBN.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.


Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareSmall CapGeneralPartner ContentPasithea
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!